Stay updated on VIP152 Dose Escalation Study in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the VIP152 Dose Escalation Study in Advanced Cancer Clinical Trial page.

Latest updates to the VIP152 Dose Escalation Study in Advanced Cancer Clinical Trial page
- Check6 days agoChange DetectedThe site revision identifier changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check13 days agoChange DetectedFull study details and metadata are now visible on the page, including the overview, design, eligibility criteria, enrollment locations, outcomes, and related MeSH terms and sponsor information. Previously, the page displayed a 403 Forbidden error, blocking access to this content.SummaryDifference74%

- Check19 days agoChange DetectedThe page now renders a 403 Forbidden error page, indicating access to the study record is blocked, with a minimal header and a Home link. The original study content and related items have been removed.SummaryDifference20%

- Check27 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, signaling a new edition of the record. This update reflects an updated documentation/version of the page rather than substantive changes to study data or content.SummaryDifference0.0%

- Check41 days agoChange DetectedThe page's revision badge was updated from v3.6.5 to v3.6.6, reflecting a new deployment version. This change does not alter the study details presented on the page.SummaryDifference0.0%

- Check48 days agoChange DetectedThe study record now includes an additional identifier/funding note: '2014 ( U.S. NIH Grant/Contract )'. This reflects NIH funding involvement for the study but does not change the study design, eligibility, or reported results.SummaryDifference0.0%

Stay in the know with updates to VIP152 Dose Escalation Study in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VIP152 Dose Escalation Study in Advanced Cancer Clinical Trial page.